Articles tagged "Immunosuppression"

2019 American Transplant Congress
Impact of Protease Inhibitor-Based Anti-Retroviral Therapy on Tacrolimus Intrapatient Variability in HIV+ Kidney Transplant Recipients
M. H. Cooper, I. E. Dunne, S. A. Kuten, A. E. Cantwell, E. A. Graviss, D. T. Nguyen, M. J. Hobeika, A. O. Gaber
Houston Methodist Hospital, Houston, TX
*Purpose: High tacrolimus (FK) intra-patient variability (IPV) has been associated with inferior outcomes in solid organ transplantation. HIV+ transplant recipients have been shown to experience…
2019 American Transplant Congress
Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
J. Arreola Guerra¹, R. Reyes Acevedo², A. Chew Wong¹, F. Haro Alcalde¹, L. Zuñiga Macias¹, R. Delgadillo Castañeda², R. Villafan³
¹Internal Medicine and Nephrology, Centenario Hospital Miguel Hidalgo, Aguascalientes, Mexico, ²Transplantation, Centenario Hospital Miguel Hidalgo, Aguascalientes, Mexico, ³Universidad Autonoma de Aguascalientes, Aguascalientes, Mexico
*Purpose: Tacrolimus (TAC) is part of the immunosuppression scheme of more than 95% of patients after kidney transplantation in Mexico. Low TAC tacrolimus trough levels…
2019 American Transplant Congress
Donor Derived Neoplasia: Will It Be a Risk after Clinical Pig Organ Xenotransplantation?
A. Jagdale¹, H. Iwase¹, E. Klein², D. Cooper¹
¹Surgery, University of Alabama at Birmingham, Birmingham, AL, ²Surgery, University of Pittsburgh, Pittsburgh, PA
*Purpose: The survival of the nonhuman primates with life-supporting pig kidney grafts has increased substantially (to >1 year). As clinical pig organ xenotransplantation draws closer,…
2019 American Transplant Congress
Utilization of LCP-Tacrolimus (ENVARSUS XR) in Simultaneous Pancreas and Kidney (SPK) Transplant Recipients
J. Torabi, A. Campbell, E. Akalin, M. Ajaimy, Y. Azzi, C. Pynadath, L. Liriano-Ward, J. P. Rocca, J. A. Graham
Montefiore Medical Center, Bronx, NY
*Purpose: The use of extended release tacrolimus (LCPT) allows for slow release of drug and once-daily dosing in transplant recipients. The improved bioavailability and decreased…
2019 American Transplant Congress
Breaking Concepts: 10-year Follow-Up of the Everolimus versus Azathioprine Heart Transplant Multi-National Study
J. A. Kobashigawa¹, R. Starling², E. Passano¹, P. Bernhardt³, B. Azarbal¹, R. Cheng¹, F. Esmailian¹, K. Khush⁴, D. Mancini⁵, J. Patel¹, T. Sato¹, S. Varnous⁶
¹Smidt Heart Institute at Cedars-Sinai, Los Angeles, CA, ²Cleveland Clinic, Cleveland, OH, ³Novartis Pharmaceuticals, Basel, Switzerland, ⁴Stanford University, Palo Alto, CA, ⁵Mount Sinai, New York, NY, ⁶APHP, Pitié‐Salpétrière, Sorbonne University, Paris, France
*Purpose: This study is the 10-year follow-up of a randomized double-blind prospective trial that compared everolimus (1.5 mg or 3 mg) to azathioprine. In this…
2019 American Transplant Congress
Belatacept Treated Patients Experience Improved Health-Related Quality of Life and Lower Symptom Distress Compared to Cyclosporine Treated Patients: An Analysis of the Benefit and Benefit-EXT Cohorts
M. J. Everly¹, I. Purnajo¹, J. L. Beaumont¹, M. Polinsky², E. Alemao²
¹Terasaki Research Institute, Los Angeles, CA, ²Bristol Myers Squibb, Princeton, NJ
*Purpose: New immunosuppressive agents in transplant should not only be efficacious but also help patients feel better (i.e. lower patient reported symptoms and improve health…
2019 American Transplant Congress
Islet Xenotransplantation: A Quest for Clinically Available Immunosuppression Regimens
Z. W. Fitch¹, Q. Gao¹, R. P. Davis¹, M. S. Mulvihill¹, M. Song¹, F. Leopardi¹, M. Ribeiro¹, T. How¹, K. Reimann², G. R. Devi¹, B. H. Collins¹, A. D. Kirk¹
¹Surgery, Duke University, Durham, NC, ²University of Massachusetts, Worcester, MA
*Purpose: Porcine islet xenotransplantation has progressed significantly in non-human primate (NHP) studies. However, all successful NHP studies have relied upon immunosuppressive regimens that utilize drugs…
2019 American Transplant Congress
Effect of ATG on Monocytic Myeloid-Derived Suppressor Cells and Its Associated Mechanisms in Kidney Transplantation Recipients
Y. Jiang, X. Zhang
Beijing Chao-yang Hospital, Beijing, China
*Purpose: Myeloid-derived suppressor cells (MDSCs) consist of heterogeneous myeloid progenitors and precursors that was first defined in cancer patients and are characterized by a immunoregulatory…
2019 American Transplant Congress
Efficacy of Belatacept Conversion Protocols
M. Yazdi, J. Kahwaji, S. Meguerditchian, R. Lee
Kaiser Los Angeles Medical Center, Los Angeles, CA
*Purpose: Belatacept (bela) is approved for de novo use in kidney transplantation. Conversion from CNI to bela is utilized for various reasons. Conversion is off-label…
2019 American Transplant Congress
Abatacept as Rescue Immunosuppression after Calcineurin Inhibitor Treatment Failure in Renal Transplantation
I. R. Badell, P. Vasanth, A. B. Farris, J. M. Robertson, G. M. Karadkhele, C. P. Larsen
Emory University School of Medicine, Atlanta, GA
*Purpose: A majority of kidney transplant recipients receive calcineurin inhibitor (CNI)-based immunosuppression. However, some do not tolerate CNIs and require other immunosuppressive strategies. Until recently,…